Archive for March 3rd, 2012

SCLN discontinues SCV-07 trial. ARNA files MAA. KERX Phase 3 Multiple myeloma update

Mar 03, 2012 No Comments by

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)  announced that it has decided to discontinue its Phase 2b trial of SCV-07 in patients with oral mucositis (OM) after analysis showed that it would not meet the pre-specified efficacy endpoints. Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) mentioned in its annual filing today that its Phase 3 trial of KRX-0401 (perifosine) in patients with Multiple […]

Daily News Read more